Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cue Biopharma, Inc.

0.7851
-0.0715-8.35%
Post-market: 0.7850-0.0001-0.01%19:25 EDT
Volume:136.33K
Turnover:110.19K
Market Cap:59.16M
PE:-1.09
High:0.8566
Open:0.8566
Low:0.7790
Close:0.8566
Loading ...

BRIEF-Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789

Reuters
·
15 Apr

Cue Biopharma Inc - Common Stock and Warrants Sold at $0.79, Pre-Funded Warrants at $0.789

THOMSON REUTERS
·
15 Apr

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

THOMSON REUTERS
·
15 Apr

BRIEF-Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments

Reuters
·
15 Apr

Cue Biopharma Starts Underwritten Equity Offering

MT Newswires Live
·
15 Apr

Cue Biopharma announces common stock, warrant offering, no amount given

TIPRANKS
·
15 Apr

Cue Biopharma receives $12M upfront in CUE-501 license pact

TIPRANKS
·
15 Apr

Cue Biopharma Announces Proposed Public Offering

THOMSON REUTERS
·
15 Apr

Cue Biopharma Announces Proposed Public Offering

GlobeNewswire
·
15 Apr

Boehringer Ingelheim and Cue Biopharma Partner to Develop Treatment for Autoimmune and Inflammatory Diseases

THOMSON REUTERS
·
15 Apr

Cue Biopharma Inc: Co Is Also Eligible to Earn up to About $345 Mln in Milestone-Based Payments

THOMSON REUTERS
·
15 Apr

Cue Biopharma to Host Business Update Call and Webcast

GlobeNewswire
·
15 Apr

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

GlobeNewswire
·
15 Apr

Cue Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
03 Apr

Cue Biopharma Price Target Maintained With a $2.00/Share by Citizens Capital Markets

Dow Jones
·
02 Apr

Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
02 Apr

Piper Sandler Sticks to Its Buy Rating for Cue Biopharma (CUE)

TIPRANKS
·
01 Apr

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
01 Apr

Cue Biopharma FY24 EPS ($0.72) Up From ($1.11) YoY; Revenue $9.287M Up From $5.490M YoY

Benzinga
·
01 Apr

Cue Biopharma, Inc. Q4 Basic EPS USD -0.13

THOMSON REUTERS
·
01 Apr